secwatch.observer — SEC 8-K summary
======================================

Issuer:     IOVANCE BIOTHERAPEUTICS, INC. (IOVA)
CIK:        0001425205
Form:       8-K
Filed at:   2026-10-05T21:00:54+00:00
Accession:  0001104659-26-113763
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Iovance raises FY2026 revenue guidance to $410M–$420M, ~15% above prior range at midpoint
--------------------------------------------------------------------------------

- FY2026 revenue guidance raised to $410M–$420M; midpoint is $55M (~15%) above prior $350M–$370M range.
- 2Q26 revenue exceeded guidance by more than 10%; ~$304M cash as of June 30, 2026 supports runway into 2H28.
- ~100 authorized treatment centers as of Oct 5, 2026; ~2,000 patients treated with commercial and clinical Iovance TIL products.
- 5-year Amtagvi data: 31.4% ORR, 19.7% OS, mDOR 36.5 months; real-world ORR ~44% and 52% in patients with ≤2 prior lines.
- TILVANCE-301 Phase 3 frontline melanoma trial (N=670, 80+ sites) enrolls on track; IOV-LUN-202 NSCLC showed 25.6% ORR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926113763/0001104659-26-113763-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1425205/000110465926113763/tm2627047d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-113763

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer